Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

Blackstone BDC Insider Purchase Defies Analyst Downgrades

Robert Sasse by Robert Sasse
November 14, 2025
in Analysis, Earnings, Insider Trading
0
Blackstonecured Lending Fund Stock
0
SHARES
99
VIEWS
Share on FacebookShare on Twitter

A significant insider transaction is drawing attention to Blackstone Secured Lending Fund as market experts recalibrate their expectations. While several financial firms reduced their price targets following the company’s latest earnings release, a corporate trustee has made a substantial personal investment. This contrasting activity raises questions about whether the business development company’s shares might be positioned for an unexpected recovery.

Strong Fundamentals Amid Market Adjustments

Despite recent challenges, Blackstone Secured Lending Fund maintains impressive operational metrics. The BDC’s portfolio demonstrates remarkable resilience with a near-zero default rate of just 0.1%. An overwhelming 97.5% of its investments are allocated to first-lien, secured loans—a conservative approach that provides substantial protection during economic uncertainty.

The company continues to demonstrate growth momentum, deploying over $1 billion in new investments during the third quarter. Its strategic emphasis on floating-rate loans offers additional security against interest rate fluctuations while supporting consistent earnings generation.

Analyst Revisions Follow Quarterly Results

The November 10 earnings report presented a mixed picture that prompted market researchers to adjust their valuations. Although the net investment income of $0.82 per share comfortably exceeded the quarterly dividend of $0.77, the net asset value per share experienced a slight decline to $27.15. This decrease stemmed from $57 million in realized and unrealized losses, representing a notable increase from the previous quarter.

Should investors sell immediately? Or is it worth buying Blackstonecured Lending Fund?

Multiple financial institutions responded with price target reductions. RBC Capital Markets lowered its objective from $32 to $29, B. Riley adjusted from $32 to $30, and Keefe Bruyette reduced from $30 to $29. Importantly, all three maintained their positive ratings of “Outperform” or “Buy.” Wells Fargo maintained a more cautious stance with its $26 target and “Equal Weight” rating.

Insider Vote of Confidence

Against this backdrop of analyst revisions, Trustee James F. Clark executed a meaningful purchase of 2,000 shares at $26.68 per share. This transaction arrives during a period of market reassessment and may signal confidence in the company’s underlying financial health.

The average analyst price target of approximately $29.78 remains substantially above the current trading level, suggesting potential upside despite recent adjustments. The upcoming quarterly report in February 2026 will reveal whether the insider’s market timing proves prescient or if the more restrained analyst perspective better reflects the company’s trajectory.

Ad

Blackstonecured Lending Fund Stock: Buy or Sell?! New Blackstonecured Lending Fund Analysis from February 7 delivers the answer:

The latest Blackstonecured Lending Fund figures speak for themselves: Urgent action needed for Blackstonecured Lending Fund investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 7.

Blackstonecured Lending Fund: Buy or sell? Read more here...

Tags: Blackstonecured Lending Fund
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

Deluxe Stock
Analysis

Deluxe Stock Gains Momentum on Successful Fintech Transition

February 6, 2026
Hydrofarm Holdings Inc Stock
Analysis

Hydrofarm Holdings: Q4 2025 Earnings Report Date Approaches

February 6, 2026
Northeast Bancorp Stock
Analysis

Northeast Bancorp Reports Robust Loan Growth Amid Strong Quarterly Performance

February 6, 2026
Next Post
Ryohin Keikaku Stock

Ryohin Keikaku Shares Surge on Exceptional Financial Performance

BitMine Stock

Leadership Shakeup at BitMine Coincides With New Short ETF Launch

BridgeBio Pharma Stock

BridgeBio Pharma: A High-Stakes Investment Proposition

Recommended

Anticipating Navigator Holdings Quarterly Earnings Report Analysts Predict 030 EPS

2 years ago
Sandy Spring Stock

Sandy Spring Bancorp’s Final Chapter: A New Era Under Atlantic Union

3 months ago
Certara Stock

Certara Stock: Regulatory Milestone and Strong Fundamentals Fuel Recovery Hopes

6 months ago
Meta Stock

Meta Faces Mounting Pressure from Regulators and Strategic Shifts

2 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Vir Biotechnology’s 2026 Pipeline: A Year of Pivotal Clinical Data

Tellurian Acquisition Finalized as Woodside Takes Control

Coherus BioSciences Forges Key Oncology Alliance with Janssen

TCG BDC Investors Await Key Financial Milestones

Navigating Change: Schnitzer Steel’s Digital and Structural Evolution

Akso Health Group Pivots to Oncology with Global Patient Initiative

Trending

Deluxe Stock
Analysis

Deluxe Stock Gains Momentum on Successful Fintech Transition

by Kennethcix
February 6, 2026
0

Deluxe Corporation is successfully shedding its legacy identity as a check-printing specialist. The company's strategic pivot toward...

Hydrofarm Holdings Inc Stock

Hydrofarm Holdings: Q4 2025 Earnings Report Date Approaches

February 6, 2026
Northeast Bancorp Stock

Northeast Bancorp Reports Robust Loan Growth Amid Strong Quarterly Performance

February 6, 2026
Vir Biotechnology Stock

Vir Biotechnology’s 2026 Pipeline: A Year of Pivotal Clinical Data

February 6, 2026
Tellurian Stock

Tellurian Acquisition Finalized as Woodside Takes Control

February 6, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Deluxe Stock Gains Momentum on Successful Fintech Transition
  • Hydrofarm Holdings: Q4 2025 Earnings Report Date Approaches
  • Northeast Bancorp Reports Robust Loan Growth Amid Strong Quarterly Performance

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com